PMID- 37944964
OWN - NLM
STAT- Publisher
LR  - 20231109
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
DP  - 2023 Nov 10
TI  - Effect of Dapagliflozin on Ventricular Remodeling and Prognosis in Patients with 
      Coronary Atherosclerotic Heart Disease Undergoing Percutaneous Coronary 
      Intervention.
LID - AT9450 [pii]
AB  - OBJECTIVE: Acute coronary syndrome (ACS) is a common cardiovascular complication 
      in patients with type 2 diabetes mellitus (T2DM) and significantly increases the 
      risk of disability and death in T2DM patients. Dapagliflozin inhibits blood 
      glucose reabsorption, improves insulin resistance, and reduces the occurrence of 
      long-term adverse cardiovascular events, indicating the importance of 
      Dapagliflozin as a drug for type 2 diabetes patients and its close relationship 
      with coronary atherosclerotic heart disease. At present, there are few studies on 
      the effects of Dapagliflozin intervention on ventricular remodeling and 
      myocardial microperfusion in patients with ACS combined with T2DM after PCI. 
      METHODS: Between January 2019 and August 2023, a total of 35 patients diagnosed 
      with Coronary atherosclerotic heart disease and T2DM were chosen as the 
      observation group using a multi-stage cluster sampling method. Concurrently, 35 
      patients with similar age, height, weight, and healthy physical examination 
      results were selected as the control group during the same time frame. We 
      collected demographic data, symptoms and underlying diseases of the two groups 
      Before enrollment and 6 months after discharge and compared the data between the 
      two groups. Subsequently, multivariate logistic regression analysis was employed 
      to identify indicators with statistically significant differences and to 
      summarize the potential risk factors that could impact ventricular remodeling in 
      patients with Coronary atherosclerotic heart disease and T2DM. RESULTS: There was 
      significant difference in LDL-C between the two groups, and the difference was 
      statistically significant (P < .05). After treatment, the levels of hs-CRP, FBG, 
      HbAlc and IL-6 in both groups were significantly decreased, and the decrease was 
      more obvious in the observation group, with statistical significance (P < .05). 
      These results indicated that Dapagliflozin intervention could significantly 
      inhibit postoperative inflammation in patients with ACS combined with T2DM after 
      PCI. LVMI of Observation group patients was significantly higher than Comparison 
      group, LVEDD and ESVI of Observation group patients were significantly lower than 
      Comparison group. The difference was statistically significant (P < .05). These 
      results indicated that Dapagliflozin intervention could significantly inhibit the 
      improvement of blood glucose index, ventricular remodeling and myocardial 
      microperfusion in patients with ACS combined with T2DM after PCI. After 
      treatment, TIMI Flow Count Frame Count (CTFC) level and Myocardial Perfusion 
      (TMPG) level in the observation group were significantly lower than those in the 
      comparison group, and the difference was statistically significant (P < .05). 
      These results indicated that Dapagliflozin intervention could significantly 
      inhibit ventricular remodeling and improve myocardial microperfusion in patients 
      with ACS combined with T2DM after PCI. CONCLUSION: Dapagliflozin intervention can 
      significantly inhibit inflammatory indexes in patients with Coronary 
      atherosclerotic heart disease combined with T2DM after PCI, promote the 
      improvement of blood glucose indexes, ventricular remodeling and myocardial 
      microperfusion, and reduce the risk of occurrence.
FAU - Ye, Lu
AU  - Ye L
FAU - Wang, Kun
AU  - Wang K
FAU - Sheng, Hui
AU  - Sheng H
FAU - Shi, Xiajun
AU  - Shi X
FAU - Yan, Ling
AU  - Yan L
LA  - eng
PT  - Journal Article
DEP - 20231110
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
SB  - IM
EDAT- 2023/11/10 00:44
MHDA- 2023/11/10 00:44
CRDT- 2023/11/09 20:12
PHST- 2023/11/10 00:44 [medline]
PHST- 2023/11/10 00:44 [pubmed]
PHST- 2023/11/09 20:12 [entrez]
AID - AT9450 [pii]
PST - aheadofprint
SO  - Altern Ther Health Med. 2023 Nov 10:AT9450.